Categories Cancer Treatment

Study: Early trial of new vaccine shows promise for treating KRAS-mutated pancreatic and colon cancers

A vaccine for treating pancreatic and colon cancers with a biomarker known as a KRAS mutation produced a strong immune response in people at high risk of recurrence in an early clinical trial. This promising vaccine is now being studied in a larger clinical trial. (Posted 12/9/25)

Study: Cancer patients with certain inherited mutations have cancer outcomes similar to those without inherited mutations

People with an inherited mutation in certain genes, including ATM, CHEK2, PALB2, BRCA or Lynch syndrome genes, have an increased risk of cancer. In this study, researchers wanted to know whether cancer patients with inherited mutations had a different chance of survival than patients without an inherited mutation in these genes. These results showed that, although the risk of cancer is increased, there is no difference in survival after a diagnosis of breast, pancreatic or colorectal cancer with or without these genetic changes. (posted 11/20/25)

Study: Exercise may delay the return of colon cancer and help people live longer

People who participated in a structured exercise program following completed treatment for colon cancer experienced more time without cancer growth and lived longer than those who did not. This study suggests that regular, moderate-intensity exercise can benefit the long-term health of people with early-stage colon cancer. (Posted 11/05/25)

Study: Combination treatment for metastatic castration-resistant prostate cancer may be especially effective for people with BRCA1 or BRCA2 mutations

This review summarizes the results of the TALAPRO2 study. It looked at how well the PARP inhibitor Talzenna (talazoparib) works for treating metastatic castration-resistant prostate cancer (mCRPC). Talzenna appears to be most effective for people with BRCA1 or BRCA2 mutations but is also effective for people with certain other mutations. (posted 9/30/25)

Study: Breast cancer treatment combination and dose improves survival in people with inherited BRCA1 and BRCA2 mutations

Treatment before surgery with a combination of targeted therapy and chemotherapy resulted in longer survival for people with an inherited BRCA1 or BRCA2 mutation who have early-stage breast cancer. The study evaluated a new dosing strategy that made it possible to safely combine Lynparza (olaparib) and chemotherapy (carboplatin). (Posted 8/31/25)

Update: FDA in the News: FDA approvals and health information on breast cancer

This XRAY review reports new treatments approved by the FDA for early and metastatic breast cancer and educational resources about women's health. (Posted 8/4/25)

Study: FDA approves new targeted therapy for advanced pancreatic cancer

A new treatment called Bizengri has been approved by the FDA for patients with advanced or metastatic pancreatic cancer. This treatment targets pancreatic cancer or non-small cell lung cancers that have a rare tumor mutation called an NRG1 fusion. (Posted 7/24/25)

Study: New FDA approval of Itovebi, a drug that may improve treatment for certain advanced or metastatic breast cancers

About one-third of hormone receptor-positive (HR-positive), HER2-negative metastatic breast cancers have a PIK3CA tumor mutation that can increase cancer growth and lead to treatment resistance. A new targeted therapy, Itovebi (inavolisib), improved patient outcomes when combined with standard treatment. This led to the recent FDA approval of the drug. (Posted 7/3/25)

Study: Enhertu shows promising results for HER2-low and HER2-ultralow metastatic breast cancer

Recent study results show that a new targeted treatment works better than standard chemotherapy for people with metastatic hormone receptor-positive breast cancers with low or ultralow HER2 status. (Posted 5/15/25)

Study: Two immunotherapy drugs are better than one for some metastatic colorectal cancers

Combining two immunotherapy drugs is a more effective treatment for certain metastatic colorectal cancers than using either treatment drug alone. Used together, Opdivo (nivolumab) plus Yervoy (ipilimumab) slowed cancer growth in MSI-High metastatic colorectal cancers, a type of colorectal cancer often found in Lynch syndrome. The FDA approved this combined treatment for MSI-High metastatic colorectal cancer after progression with chemotherapy. (Posted 4/30/25)

Este artículo está disponible en español